Prognosis and staging of AL amyloidosis

• Verfasst von: Dittrich, Tobias [VerfasserIn]
• Verfasst von: Kimmich, Christoph [VerfasserIn]
• Verfasst von: Hegenbart, Ute [VerfasserIn]
• Verfasst von: Schönland, Stefan [VerfasserIn]
• Titel: Prognosis and staging of AL amyloidosis
• Verf.angabe: Tobias Dittrich, Christoph Kimmich, Ute Hegenbart, Stefan O. Schönland
• E-Jahr: 2020
• Jahr: June 22, 2020
• Umfang: 12 S.
• Fussnoten: Gesehen am 11.09.2020
• Titel Quelle: Enthalten in: Acta haematologica
• Ort Quelle: Basel : Karger, 1948
• Jahr Quelle: 2020
• Band/Heft Quelle: 143(2020), 4, Seite 388-400
• ISSN Quelle: 1421-9662
• DOI: doi:10.1159/000508287
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 173052043X

Abstract

The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly. In this context, accurate estimates of prognosis in AL, which allow for reliable patient advice and for example comparison of different therapies, are particularly important to clinicians. Some biomarkers and especially the genetic background of the underlying clonal disease as evaluated by interphase fluorescence in situ hybridization even have predictive value, enabling an appropriate treatment selection. Derived from the most frequently involved organs in AL, heart and kidney, this review focuses on overall survival and renal survival. A comprehensive overview and summary of reported prognostic factors and biomarkers in AL is given and the most important and validated factors are highlighted. Finally, established staging systems in AL as well as validated and perspective response criteria are presented.